Table 4.

Two-Hour Pain-Relief and Pain-Freedom From Migraine in Presence or Absence of Baseline Allodynia in the Ketorolac vs Sumatripan vs Placebo Nasal Spray Migraine Study

	Placebo % (95% CI)	Ketorolac NS % (95% CI)	P-Value vs Placebo	Sumatriptan NS % (95% CI)	P-Value vs Placebo	P-Value vs Ketorolac
No Allodynia
2-HR Pain Relief	38.2 (21.0–55.4)	70.9 (50.0–87.9)	.004	70.6 (54.4–86.7)	.004	.968
2-HR Pain Freedom	11.7 (3.5–23.2)	45.2 (26.6–63.7)	.001	32.3 (15.8–48.9)	.042	.201
Any Allodynia
2-HR Pain Relief	40.1(11.9–68.1)	75.0 (54.2–95.8)	.027	66.7 (39.6–93.7)	.114	.598
2-HR Pain Freedom	33.3 (6.3–60.3)	40.0 (16.5–63.5)	.693	46.7 (18.1–75.2)	.449	.679
Mod-Severe Allodynia
2-HR Pain Relief	30.0 (−4.5–64.5)	76.9 (50.4–99.4)	.012	54.5 (19.5–89.6)	.190	.233
2-HR Pain Freedom	30.0 (−4.5–64.5)	38.4 (7.8–69.1)	.663	36.3 (2.5–70.2)	.757	.905

^*Any allodynia ≥2 allodynic symptoms; moderate to severe: ≥3 allodynic symptoms. HR =hour.